02Transforming patients' lives
Our Portfolio

Atopic dermatitis (AD)

Atopic dermatitis is a non-contagious, chronic inflammatory disease characterised by recurrent skin inflammation. Beyond physical symptoms such as dryness, itchiness, redness and inflammation of the skin, it can significantly impact emotional well-being and daily life.

Immune Disease

EBGLYSS®

(lebrikizumab)

Biologic that selectively targets IL 13; approved in Europe for moderate-to-severe AD in eligible adult and adolescent patients.

Cordran® Tape

(flurandrenolide)

Topical corticosteroid (commercially available in Japan and the United States).

Psoriasis

Psoriasis is a chronic, autoimmune skin disorder characterised by inflammation, manifesting through reddish, scaly patches appearing on a wide range of areas. It can have a profound impact on social, psychological and physical quality of life. Disease burden can extend beyond the skin—it is often linked to comorbidities such as psoriatic arthritis and cardiovascular disease—and calls for a holistic approach to management.

Immune Disease

Ilumetri®

(tildrakizumab)

Biologic targeting IL-23 (p19) for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy.

Wynzora® Cream

(Calcipotriene, Betamethasone dipropionate)

Once-daily topical treatment for mild-to-moderate plaque psoriasis, including the scalp.

Skilarence®

(dimethyl fumarate)

Oral fumaric acid ester for adults with moderate-to-severe plaque psoriasis requiring systemic therapy.

Hidradenitis suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by inflammatory and painful nodules, abscesses and/or draining tunnels that usually develop in the major skin folds, impairing self-esteem, relationships and quality of life

Alopecia areata

An immune-mediated skin disease that leads to patchy or disseminated hair loss and can carry a high psychological and emotional burden.

Actinic keratosis (AK)

Actinic keratosis is a frequently diagnosed precursor of keratinocyte cancer characterised by rough, scaly lesions on sun-exposed areas. As a chronic and recurrent condition, it can increase the risk of developing squamous cell carcinoma, reinforcing the importance of early detection and treatment.In the United States, AK is the second most common diagnosis in dermatology. It is estimated that more than 40 million Americans develop actinic keratoses each year.5

Klisyri®

(tirbanibulin)

Short-course topical field therapy for AK on the face or scalp (where approved).

Actikerall®

(Salicylic Acid,5-Fluorouracil)

Topical treatment used for AK lesions and adjacent sun-damaged skin (where approved).

Solaraze®

Solaraze®

Lesion-directed topical combination therapy for AK (where approved).

Other immune-mediated conditions

  • Vitiligo
  • Palmoplantar pustulosis

Keratinocyte cancer (including non-melanoma skin cancers)

  • Basal cell carcinoma
  • Squamous cell carcinoma
  • Cutaneous T-cell lymphoma

Acne

Acne is one of the most common inflammatory dermatoses treated around the world, and is estimated to affect ~9.4% of the world’s population23. Acne causes lesions on the face, upper arms, trunk and back. While more common in adolescents and young adults, it is not limited to this age group. The impact of acne also goes beyond physical symptoms, increasing depressive symptoms and diminishing self-confidence and self-worth24

Seysara®

(sarecycline)

Seysara® is a first-in-class, third generation, tetracycline-derived oral antibiotic for the treatment of moderate to severe non-nodular acne vulgaris (AV) in patients aged 9 years and older.

Ciclopoli®

(ciclopirox)

Ciclopoli® is a once-daily topical treatment indicated for mild-to-moderate fungal infections of the nails.

Onychomycosis

Onychomycosis, or nail fungus, is the leading cause of nail infections, responsible for nearly half of all nails disorder consultations25. More common in males and known to increase with age in both genders26, it is initially characterized by white, yellow, or black spots at the nail’s edge or base near the cuticle, encompassing the entire nail as it progresses.  This contagious disease can infect other nails or other people through contact with contaminated surfaces, causing significant mental discomfort due to its persistent nature.

1. Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019 Sep;104(3):174-177.

2. Barbarot S, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018 Jun;73(6):1284-1293. doi: 10.1111/all.13401. Epub 2018 Feb 13. PMID: 29319189.

3. Silverberg J, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.

4. Bernardo D, et al. Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2023;24, 753– 764.

5. Moyle M, et al. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–768.

6. Gonçalves F, et al. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context 2021;10:2021-1-7.

7. Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547.

8. Ultsch M, et al. Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339.

9. Guttman-Yassky E, et al. Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin. Presented at the Fall Clinical Dermatology Conference; October 20, 2023.

10. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May;36:m1590. doi:10.1136/bmj.m1590.

11. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J Invest Dermatol. 2014 Jun;134(6):1542–1551. doi: 10.1038/jid.2013.508. Epub 2013 Nov 27. PMID: 24284419.

12. Mrowietz U, et al. Presented at the 25th World Congress of Dermatology (WCD) July 3-8 ,2023, Singapore, Abstract 799

13. Topp CW, et al. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84:167–76.

14. Pinter A, et al, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M; trial investigator group. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228–236. doi: 10.1111/jdv.17734.

15. Præstegaard M, et al. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. doi: 10.25251/skin.4.supp.61.

16. Præstegaard M, et al. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. doi: 10.25251/skin.4.supp.61.

17. Stein Gold L, et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021 Apr;20(4):420-425.

18. Bewley A, et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. J Dermatolog Treat. 2022 33 (8): 3191-3198.

19. PsO PowerBI Dashboard (IQVIA Midas data).

20. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007 Sep;33(9):1099-101. doi: 10.1111/j.1524-4725.2007.33224. x.

21. Wilmer EN, Gustafson CJ, Ahn CS, Davis SA, Feldman SR, Huang WW. Most common dermatologic conditions encountered by dermatologists and nondermatologists. Cutis. 2014 Dec;94(6):285-92.

22. AK PowerBI Dashboard (IQVIA Midas data).

23. Tan JKL, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015 Jul;172 Suppl 1:3-12. doi: 10.1111/bjd.13462. PMID: 25597339.

24. Dalgard F, Gieler U, Holm JØ, Bjertness E, Hauser S. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol. 2008 Nov;59(5):746-51. doi: 10.1016/j.jaad.2008.07.013. PMID: 19119094.

25. Maskan Bermudez N, et al. Onychomycosis: Old and New. Journal of Fungi. 2023; 9(5):559.

26. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1480-91.

27. Ciclopoli® (Ciclopirox) SmPC.

28. Monti D et al,. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm. 2005 Jan;31(1):11-7.

29. Sparavigna M, et al. Physical and microbiological properties of a new nail protective medical device. J Plastic Dermatol. 2008;4(1):5-12.

30. Monti D, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol. 2010 Feb;162(2):311-7.

31. Iorizzo M et al,. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: A randomized, amorolfine controlled study using a blinded evaluator. Skin Appendage Disord. 2016 Feb;1(3):134-40.